Association of Anti‐CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis
Authors' conclusion
Anti-CCAR1 autoantibodies are specific for anti-TIF1γ-positive DM. Their presence in anti-TIF1γ-positive patients attenuates the risk of cancer to a level comparable to that seen in the general population.
Study context
- Population
- Dermatomyositis (DM) patients from 2 independent cohorts (Johns Hopkins and Stanford); patients with other rheumatic diseases and healthy controls as comparators2 cohorts
- Exposure
- Anti-CCAR1-positive vs anti-CCAR1-negative DM (by anti-TIF1γ status); cancer incidence vs general population
- Anti-TIF1γ-positive DMn = 252
- Anti-TIF1γ-negative DMn = 186reference
- Outcome
- Frequency of anti-CCAR1 autoantibodies (disease specificity), clinical features and risk of cancer vs general population
Methodological details2 independent cohorts (Johns Hopkins and Stanford), ELISA autoantibody testing, standardized incidence ratio (SIR) vs general population
- 2 independent cohorts (Johns Hopkins and Stanford)
- ELISA autoantibody testing
- SIR vs general population
Main finding
As reported in the abstract
Anti-CCAR1 positivity by anti-TIF1γ status
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | SIR (95% CI) | P value | |
|---|---|---|---|
| Cancer vs general population, anti-TIF1γ+ and anti-CCAR1+ DM · from DM onset onwardAnti-TIF1γ+/anti-CCAR1+ DM, Johns Hopkinsvs General population | 1.78 (0.77–3.51) | P = 0.172 | |
| Cancer vs general population, anti-TIF1γ+ and anti-CCAR1+ DM · from DM onset onwardAnti-TIF1γ+/anti-CCAR1+ DM, Stanfordvs General population | 1.61 (0.44–4.13) | P = 0.48 | |
| 0.20.5125Standardized incidence ratio (log scale) |
| Outcome | Healthy controls | Anti-HMGCR NM | IBM | SLE |
|---|---|---|---|---|
| Anti-CCAR1 positivity in healthy controls and other rheumatic diseases | n = 32 | 2.3% · 1 of 44 | 2.3% · 1 of 44 | 6.5% · 3 of 46 |
Anti-CCAR1 positivity in healthy controls and other rheumatic diseases
- Anti-CCAR1 not detected in any healthy control serum sample
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association of Anti‐CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti–Transcriptional Intermediary Factor 1γ–Positive Dermatomyositis. Arthritis Rheumatol. Published 9 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →